Johns Hopkins School of Medicine, United States
Disclosure information not submitted.
3G-03 - Risk of Pregnancy Loss with Vedolizumab Use during Pregnancy Compared to TNF Inhibitors in Individuals with Inflammatory Bowel Disease
Monday, August 25, 20258:45 AM - 9:00 AM ET
